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In Europe, antimicrobial resistance has been monitored since 1998 by the European Antimicrobial
Resistance Surveillance System (EARSS). We examined the relationship between penicillin nonsus-
ceptibility of invasive isolates of Streptococcus pneumoniae (an indicator organism) and antibiotic
sales. Information was collected on 1998-99 resistance data for invasive isolates of S. pneumoniae
to penicillin, based on surveillance data from EARSS and on outpatient sales during 1997 for beta-
lactam antibiotics and macrolides. Our results show that in Europe antimicrobial resistance is corre-
lated with use of beta-lactam antibiotics and macrolides. 
ntimicrobial resistance is a growing problem worldwide,
requiring international approaches. The World Health
Organization (WHO) and the European Commission have rec-
ognized the importance of studying the emergence and deter-
minants of resistance and the need for strategies for its control
(1-3). In European countries, antimicrobial resistance has been
monitored in selected bacteria from humans since 1998
through the European Antimicrobial Resistance Surveillance
System (EARSS). Funded by the European Commission,
EARSS is an international network of national surveillance
systems intended to collect comparable and reliable resistance
data. The purpose of EARSS is to document variations in anti-
microbial resistance over time and place and to provide the
basis for and assess the effectiveness of prevention programs
and policy decisions. 
One of the indicator organisms in EARSS is Streptococcus
pneumoniae. It was included for three reasons: it is of major
clinical importance for pneumonia, bacterial meningitis, and
otitis media; many countries have reported that its resistance to
penicillin is increasing; and S. pneumoniae is representative of
organisms that are transmitted in the community. 
A major risk factor for the development of resistance is
thought to be inappropriate use of antimicrobial drugs. Most
studies that have investigated the relationship of antimicrobial
use and antimicrobial resistance have been undertaken in hos-
pital, multicenter, or country settings (4-7). For infections with
penicillin-nonsusceptible S. pneumoniae (PNSP), studies have
demonstrated that at the individual level, previous use of beta-
lactam antibiotics such as penicillin is an important risk factor
(8-10). Studies on carriage of PNSP in children have shown
that sulfamethoxazole-trimethoprim (co-trimoxazole) and
macrolides such as erythromycin have also been associated
with selection of PNSP (11,12). Translated to the population
level, sales of beta-lactam antibiotics, co-trimoxazole, or mac-
rolides in a given geographic region may be proportional to
microbial resistance to penicillin. If on the European level a
relationship between antimicrobial resistance and antimicro-
bial use could be found (as in the case of S. pneumoniae and
resistance to penicillin), efforts to control antimicrobial use
and misuse could be stimulated and monitored in Europe.
We used an ecologic study design to examine the correla-
tion between use of relevant antibiotics in the outpatient set-
ting and the proportion of PNSP among invasive isolates of S.
pneumoniae in 11 European countries. 
Methods
Antimicrobial Resistance Data 
The estimated average coverage of the populations of
countries participating in EARSS is 52% (range 10% to 90%)
(13). Laboratories that participate in EARSS screen invasive S.
pneumoniae isolates for oxacillin resistance (14). When an iso-
late is found to be nonsusceptible, the EARSS protocol
requests confirmation as intermediate- or high-level resistance
to penicillin by determination of MICs. Laboratories perform
microbiologic testing and interpret results according to their
own standards. National guidelines in Europe differ; isolates
of S. pneumoniae are considered nonsusceptible to penicillin if
the MIC is >0.06 (15-18) or >0.12 (19,20) mg/L. For this
report, we use nonsusceptibility and intermediate resistance as
synonyms; PNSP isolates are either intermediate or fully
*National Institute of Public Health and the Environment, Bilthoven, the
Netherlands; †Swedish Institute for Infectious Disease Control, Solna,
Sweden; ‡The Nepi Foundation, Malmö, Sweden; and §Groningen
University Hospital, Groningen, the Netherlands 
AEmerging Infectious Diseases  •  Vol. 8, No. 3, March 2002 279
RESEARCH
resistant to penicillin. Only the first invasive isolate per patient
per quarter is reported. 
To assess the comparability of susceptibility test results, a
quality assurance exercise was performed in September 2000
among 482 laboratories from 23 countries participating in
EARSS. The concordance (agreement of reported results with
intended results) for the detection of penicillin resistance in the
three S. pneumoniae control strains was 91% (21). Laborato-
ries sent standardized data to the national EARSS data man-
ager, who checks data contents and ensures conformity with
the EARSS data format. In collaboration with WHO, an export
module from the laboratory-based software WHONET was
developed for EARSS (22). Every quarter, data are forwarded
to the central database at the National Institute of Public
Health and the Environment (RIVM), Bilthoven, Netherlands,
where the project is coordinated. 
Antimicrobial Use Data
National outpatient sales data for antibiotics from 1997
were purchased from IMS Health Global Services, London,
United Kingdom, for 13 of the 15 member states of the Euro-
pean Union. Corresponding data were obtained from the Dan-
ish Medicines Agency for Denmark and from the National
Corporation of Swedish Pharmacies for Sweden (23). The
IMS data were examined and adjusted according to the Ana-
tomic Therapeutic Classification (ATC) system used by WHO
(24). The amount in kilograms for an antimicrobial agent was
converted to a number of defined daily doses (DDD). The
DDD, which is based on the average daily dose used for the
main indication of the drug, is appropriate for comparisons of
drug use over time and in different geographic areas. For beta-
lactam antibiotics, we combined ATC groups J01C (extended-
and narrow-spectrum penicillins) and J01D (cephalosporins);
macrolides were classified under code J01F. No data were
available for the combination of trimethoprim and sulphona-
mide.  
Nonadherence 
We considered nonadherence of patients to the physician’s
prescription in individual countries as a possible confounder of
antimicrobial resistance. Branthwaite et al. reported nonadher-
ence levels from a population-based survey in seven countries
(25). Data from four of the seven countries (Spain, Belgium,
the United Kingdom, and Italy) were also captured in EARSS.
Statistical Analysis
We calculated the proportion of PNSP among all invasive
S. pneumoniae isolates from each country reported during
1998-99. Because probabilities allow only values between 0
and 1, we modeled the natural logarithm of the odds of PNSP
resistance (logodds). 
Least-square linear regression analysis was used to assess
correlation between antimicrobial use (of beta-lactam antibiot-
ics and macrolides, expressed in DDD per 1,000 population
per day) and the logodds of resistance. We correlated nonad-
herence levels with the logodds of resistance in the same way.
We calculated the Spearman coefficient of determination (r-
square) and its corresponding p value. For the calculation of
the regression lines, we weighted the data points by the inverse
of the variance of each data point. We used SAS software
(SAS Institute Inc., Release 6.03., Cary, NC).
Results
Antimicrobial Resistance
During 1998-99, 337 laboratories from 11 European Union
member states (Belgium, Finland, Germany, Ireland, Italy,
Luxembourg, Netherlands, Portugal, Spain, Sweden, and
United Kingdom) and one nonmember state (Iceland) reported
4,872 invasive S. pneumoniae isolates to EARSS. The propor-
tion of PNSP among isolates of invasive S. pneumoniae
ranged from 1% to 34% (Table) (Figure 1). Southern European
countries reported higher rates than northern European coun-
tries.
Antimicrobial Use
Data on outpatient sales of beta-lactam antibiotics and
macrolides were available for 1997 from all 15 European
Union member countries. Antimicrobial use varied widely
between countries. Sales to outpatients ranged from 3.8 to 23.6
DDD per 1,000 inhabitants per day for beta-lactam antibiotics
and from 0.97 to 5.98 DDD for macrolides. The three coun-
tries with the highest reported use were France, Spain, and
Portugal for beta-lactam antibiotics and France, Spain, and
Italy for macrolides; the three countries with the lowest use
were the Netherlands, Germany, and Austria for beta-lactam
antibiotics and Sweden, the Netherlands, and Finland for mac-
rolides. 
Correlation
For 11 countries, information was available for both anti-
microbial resistance and antimicrobial use. Linear regression
of the correlation of use of beta-lactam antibiotics and the
logodds of resistance showed an r-square of 0.80 (p=0.0002)
(Figure 2). The equation for the regression is 
logodds of resistance =(-3.94)+(0.16xDDD). 
For the use of macrolides, we calculated an r-square of
0.46. Figure 3 shows the graph for nonadherence to antibiotics
and the logodds of resistance. The r-square is 0.8 (p=0.2). 
Discussion
We present for the first time Europe-wide, country-spe-
cific, representative data on antimicrobial resistance collected
by EARSS. Using an ecologic study design, we demonstrate
through the correlation with data on antimicrobial use one
aspect of the usefulness of surveillance for antimicrobial resis-
tance. The results from 11 European countries show a linear
relationship between use of beta-lactam antibiotics and mac-
rolides and the proportion of PNSP among all invasive
S. pneumoniae isolates. RESEARCH
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EARSS data show that resistance for PNSP follows a
north-south gradient. Southern European countries have higher
proportions of PNSP than countries in northern Europe. A pos-
sible reason for this observation could be the difference in
antimicrobial use, which also tends to be higher in southern
European countries. If use of relevant antibiotics (beta-lactam
antibiotics and macrolides) and the logodds of resistance are
modeled through linear regression, a strong linear and statisti-
cally significant relationship is demonstrated. 
Our findings agree with those of Austin et al., who mod-
eled the relationship between antimicrobial use and endemic
resistance, based on population genetic methods and epidemi-
ologic observations (26). The correlation in Figure 2 is consis-
tent with the model developed by Austin et al. on theoretical
grounds. 
We correlate antimicrobial sales data for 1997 with antimi-
crobial resistance data for 1998 and 1999. Others have
observed that after a lag time of 1 or more years, changes in
antimicrobial use may be followed by changes in antimicrobial
resistance (27,28). Therefore, we believe that it is reasonable
to correlate antimicrobial sales data in 1997 with antimicrobial
resistance data from 1998-99.
We address several limitations in our study. First, because
it is an ecologic study, we can make no inferences on the indi-
vidual level. Second, resistance rates in some countries (Table)
are calculated from a relatively limited number of isolates.
However, based on communications with EARSS country rep-
resentatives, our data are consistent with antimicrobial resis-
tance levels derived from other sources (29). Third, an
explanation for the differences in antimicrobial resistance
could be sampling bias: clinicians in southern European coun-
tries may request blood cultures more frequently than their
northern European colleagues, who may sample only in case
of empirical treatment failure. Fourth, we have not addressed
other, potentially important contributing factors for the devel-
opment of antimicrobial resistance of organisms that are trans-
mitted in the community, particularly nonadherence and over-
the-counter sales of antimicrobial agents. Both these factors
are difficult to measure. However, in 1993 nonadherence to
prescribed antimicrobial agents was assessed in a survey in six
Table. Number of submitting laboratories, number of isolates of Streptococcus pneumoniae, number (#) and percent (%R) of penicillin nonsus-
ceptible S. pneumoniae isolates, logodds of resistance (ln(%R/[1-%R]), and outpatient sales of beta-lactam antibiotics and macrolides
Country
No. of labora-
tories
No. of S. pneumo-
niae isolates        
Penicillin nonsusceptible S. pneumoniae  Outpatient sales of antibiotics in DDDa/1,000 
inhabitants/day
No. %R (95% CI) ln (%R/[1-%R]) Beta-lactam antibiotics Macrolides
Austria - - - - - 6 3.7
Belgium 96 940 131 14 (12-16) -1.82 14 4.1
Denmark - - - - - 7 2
Finland 11 211 8 4 (2-8) -3.18 8 1.9
France - - - - - 24 6.0
Germany 15 222 4 2 (1-5) -3.89 5 2.5
Iceland 2 54 1 2 (0-11) -3.89 Not available Not available
Ireland 12 157 30 19  (13-26) -1.45 11 2.5
Italy 46 194 26 13 (9-19) -1.87 15 5.1
Luxembourg 1 11 2 18 (3-52) -1.52 14 4.7
Netherlands 20 760 8 1 (0-2) -4.6 4 1.2
Portugal 12 134 25 19 (13-27)  -1.45 16 3.7
Spain 76 1,240 418 34 (31-36) -0.66 21 5.9
Sweden 24 706 21 3 (2-5) -3.48 8 1
United Kingdom 22 243 21 9 (6-13) -2.31 9 3.2
aDDD = defined daily doses; CI = confidence interval.
Figure 1. Proportions of invasive isolates of Streptococcus pneumoniae
resistant to penicillin (PNSP) among 12 European countries, 1998–99.Emerging Infectious Diseases  •  Vol. 8, No. 3, March 2002 281
RESEARCH
European countries (25). Although the number of data points
is limited, Figure 2 suggests a direct relationship between non-
adherence rates and logodds of resistance. Thus, if nonadher-
ence is also related to sales of antimicrobial agents, it could
potentially confound the relationship between use and resis-
tance. Data on the degree of over-the-counter use among Euro-
pean countries are not widely available; we know of one
Spanish and one Greek study reporting an estimate of over-
the-counter use (30,31). The influence of these and other
parameters on the level of resistance should be quantified and
understood. Finally, because children are the main reservoir of
carriage of S. pneumoniae, an age-stratified analysis would be
desirable, i.e., a correlation of resistance with antimicrobial
use among children. However, this analysis would require
more detailed use data, for example, of liquid formulations of
antibiotics.
At least two studies in northern Europe have demonstrated
that PNSP rates can be halted or even reversed when physi-
cians avoid the inappropriate prescription of antimicrobial
agents (32,33). Our study is timely because it shows that even
at the European level a correlation can be observed between
antimicrobial resistance (of S. pneumoniae to penicillin) and
antimicrobial use. In several European countries, national
action plans for the appropriate use of antimicrobial agents are
being planned or implemented; their effectiveness should be
monitored through prospective and continuous surveillance of
antimicrobial resistance and antimicrobial sales data (34-38).
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